2021年12月13日简报:国内新增本土病例49例,其中浙江38例;感染新冠可能会影响男性的生殖能力,南非一周的新增感染病例激增400%

2021-12-13 MedSci整理 MedSci整理

截至北京时间2021年12月13日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿7040万例,新增488,458例,达到270,400,

截至北京时间2021年12月13日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过2亿7040万例,新增488,458例,达到270,400,515例。累计死亡病例532.1万例,达到5,321,510例。新增死亡为5,395例。康复为242,694,784例,重症和危重症病人达到88,811例;全球新冠确诊病例超过100万例的国家达40个,112个国家病例超10万例。昨日报道:2021年12月12日简报:奥密克戎让大部分中和抗体失效,但是预计到明年春天,全球疫情全缓和

感染新冠可能会影响男性的生殖能力

日前在《自然综述-泌尿学》上发表的一篇综述论文,则更直接地指出男性感染新冠后的潜在严重后果——生育力降低。通过分析已有的证据,过去的研究,乃至SARS病毒的病例情况,本综述详尽描述了新冠病毒会如何影响睾丸组织。“在新冠重症病例中,我们知道睾丸的情况并不乐观。”本综述的通讯作者Clayton Edenfield教授说道。

具体来看,作者们指出随着对新冠研究的深入,我们对新冠入侵细胞的途径有了更好的认知。除了上述提到的ACE2受体外,新冠入侵细胞还需要一种叫做TMPRSS2的丝氨酸蛋白酶参与。不幸的是,睾丸同时能产生这两种蛋白,也使其成为了新冠病毒的易感目标,可能因此出现细胞损伤。

作者们随即给出了他们的分析。他们指出在病毒感染睾丸组织后,可能会通过多种方式来影响精子产出或是质量。比如它们会破坏血液-睾丸屏障,影响免疫能力,破坏激素平衡,或是直接作用于精原细胞。

南非疫情“震中”12月首周新增感染激增400%

据红星新闻援引外媒12月11日报道,在南非本次疫情的“震中”豪登省,12月第一周的新增感染病例激增400%,其中90%以上的感染都由奥密克戎毒株引发。本周四,南非全国新增确诊感染病例2.24万例,周五新增确诊病例1.9万例,而几周前每天仅有约200例新增病例。南非卫生部长法赫拉12月10日称,在过去一个月里,南非的新增感染病例已达到9万例。

不过,根据南非国家传染病研究所公布的最新数据,近几周来因奥密克戎感染而住院的患者中,重症率约为30%,较当地此前几波疫情减少了一半。

虽然南非流行的变异新冠病毒奥密克戎毒株所引发症状,不如德尔塔毒株严重,但大量感染者还是拖累医疗系统

南非国家传染病研究所对最近几周新增确诊病例的研究发现:大约30%的新冠住院病例是重症,不到前几轮疫情最初几周重症比例的一半;新冠患者平均住院周期更短,大约2.8天,而前几轮疫情这一数据是8天;新冠住院病例的死亡率为3%,而前几轮疫情为大约20%。

一名为南非国家传染病研究所监测住院数据的研究员说,尽管奥密克戎感染者症状没有那么严重,新增确诊病例数庞大可能依旧令南非医疗系统不堪重负,进而导致更多重症和死亡病例。

英国:奥密克戎传播速度比南非还要快

与此同时,全球各国的科学家正在密切关注本国的奥密克戎毒株,部分国家的形势似乎并不如南非一样“乐观”。

据外媒12月11日报道,伦敦卫生和热带医学学院的一组专家警告称,在没有进一步限制措施的情况下,英国将在明年1月迎来新一轮的疫情高峰。根据模型预测,在最悲观的情况下,截至明年4月底,奥密克戎毒株感染可能导致该国2.5万人至7.5万人死亡。

不仅如此,两名英国传染病专家也在近日纷纷警告称,新冠病毒奥密克戎变种在英国的传播速度似乎已经超过了南非。伦敦卫生和热带医学学院的约翰·埃德蒙兹教授在一场英国皇家医学会的研讨会上表示,奥密克戎在英国的传播速度“相当惊人”,“甚至可能比在南非还要快”。

英国卫生安全局的首席医疗顾问苏珊·霍普金斯博士表示,过去几天已收到一些奥密克戎毒株感染病例入院治疗的报告,目前正在对病例的情况进行调查。

美国20多州出现奥密克戎感染病例

据美国约翰斯·霍普金斯大学发布的全球新冠肺炎数据实时统计系统,截至美国东部时间2021年12月11日下午6点,全美共报告新冠肺炎确诊49874867例,死亡797121例。过去约24小时,美国新增确诊99246例,新增死亡906例。

《纽约时报》报道说,美国疾控中心表示,12月1日至8日,美国有22个州报告了43例奥密克戎毒株感染病例。而根据《纽约时报》的统计,美国已有27个州出现奥密克戎毒株感染病例。

美国疾控中心主任瓦伦斯基表示,过去7天美国日均新增确诊病例增长了37%,日均死亡病例上升28%。

以色列奥密克戎毒株感染病例增至55例

当地时间11日晚间,以色列卫生部发表声 明称,在过去的24小时,该国新增奥密克戎毒株确诊感染病例20例,累计确诊病例数升至55例。 此外,该国还有51例疑似感染病例。

韩国单日新冠死亡病例创新高

韩国中央防疫对策本部11日通报,韩国过去一天新增新冠死亡病例80例,创疫情暴发以来新高。 总统文在寅对疫情形势表示担忧,呼吁尽快为老年群体接种加强针,以防死亡病例数进一步攀升。 韩国新冠疫情趋紧,连日来单日新增确诊病例均在7000例左右高位。

本土病例49例,浙江新增38例本土确诊

据国家卫健委消息,12月11日0时至24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例75例:

境外输入病例26例(上海8例,广西8例,山东2例,四川2例,云南2例,辽宁1例,福建1例,广东1例,陕西1例),含1例由无症状感染者转为确诊病例(在四川);

本土病例49例(浙江38例,其中绍兴市22例、杭州市8例、宁波市8例;内蒙古10例,均在呼伦贝尔市;黑龙江1例,在哈尔滨市),含20例由无症状感染者转为确诊病例(均在浙江)。

12月11日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增确诊病例75例。 其中境外输入病例26例(上海8例,广西8例,山东2例,四川2例,云南2例,辽宁1例,福建1例,广东1例,陕西1例),含1例由无症状感染者转为确诊病例(在四川); 本土病例49例(浙江38例,其中绍兴市22例、杭州市8例、宁波市8例; 内蒙古10例,均在呼伦贝尔市; 黑龙江1例,在哈尔滨市),含20例由无症状感染者转为确诊病例(均在浙江)。 无新增死亡病例。 新增疑似病例1例,为境外输入病例(在上海)。

当日新增治愈出院病例24例,解除医学观察的密切接触者1014人,重症病例与前一日持平。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061277, encodeId=e1af20612e723, content=<a href='/topic/show?id=19cf6911561' target=_blank style='color:#2F92EE;'>#生殖能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69115, encryptionId=19cf6911561, topicName=生殖能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Nov 24 17:50:36 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764286, encodeId=a8c61e642865c, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Tue Sep 20 20:50:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414473, encodeId=c62614144e36e, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604352, encodeId=c0c31604352d9, content=<a href='/topic/show?id=71b95335396' target=_blank style='color:#2F92EE;'>#感染病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53353, encryptionId=71b95335396, topicName=感染病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=337119178396, createdName=xugc, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079483, encodeId=2f3d10e948340, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3e642424157, createdName=123a16c8m00暂无昵称, createdTime=Mon Dec 13 10:51:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079432, encodeId=83d210e9432e1, content=疫情越来越严重, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195b5478869, createdName=吉星高照4739, createdTime=Mon Dec 13 09:14:35 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061277, encodeId=e1af20612e723, content=<a href='/topic/show?id=19cf6911561' target=_blank style='color:#2F92EE;'>#生殖能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69115, encryptionId=19cf6911561, topicName=生殖能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Nov 24 17:50:36 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764286, encodeId=a8c61e642865c, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Tue Sep 20 20:50:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414473, encodeId=c62614144e36e, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604352, encodeId=c0c31604352d9, content=<a href='/topic/show?id=71b95335396' target=_blank style='color:#2F92EE;'>#感染病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53353, encryptionId=71b95335396, topicName=感染病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=337119178396, createdName=xugc, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079483, encodeId=2f3d10e948340, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3e642424157, createdName=123a16c8m00暂无昵称, createdTime=Mon Dec 13 10:51:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079432, encodeId=83d210e9432e1, content=疫情越来越严重, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195b5478869, createdName=吉星高照4739, createdTime=Mon Dec 13 09:14:35 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061277, encodeId=e1af20612e723, content=<a href='/topic/show?id=19cf6911561' target=_blank style='color:#2F92EE;'>#生殖能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69115, encryptionId=19cf6911561, topicName=生殖能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Nov 24 17:50:36 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764286, encodeId=a8c61e642865c, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Tue Sep 20 20:50:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414473, encodeId=c62614144e36e, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604352, encodeId=c0c31604352d9, content=<a href='/topic/show?id=71b95335396' target=_blank style='color:#2F92EE;'>#感染病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53353, encryptionId=71b95335396, topicName=感染病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=337119178396, createdName=xugc, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079483, encodeId=2f3d10e948340, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3e642424157, createdName=123a16c8m00暂无昵称, createdTime=Mon Dec 13 10:51:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079432, encodeId=83d210e9432e1, content=疫情越来越严重, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195b5478869, createdName=吉星高照4739, createdTime=Mon Dec 13 09:14:35 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-14 hongbochen
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061277, encodeId=e1af20612e723, content=<a href='/topic/show?id=19cf6911561' target=_blank style='color:#2F92EE;'>#生殖能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69115, encryptionId=19cf6911561, topicName=生殖能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Nov 24 17:50:36 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764286, encodeId=a8c61e642865c, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Tue Sep 20 20:50:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414473, encodeId=c62614144e36e, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604352, encodeId=c0c31604352d9, content=<a href='/topic/show?id=71b95335396' target=_blank style='color:#2F92EE;'>#感染病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53353, encryptionId=71b95335396, topicName=感染病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=337119178396, createdName=xugc, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079483, encodeId=2f3d10e948340, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3e642424157, createdName=123a16c8m00暂无昵称, createdTime=Mon Dec 13 10:51:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079432, encodeId=83d210e9432e1, content=疫情越来越严重, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195b5478869, createdName=吉星高照4739, createdTime=Mon Dec 13 09:14:35 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-14 xugc
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061277, encodeId=e1af20612e723, content=<a href='/topic/show?id=19cf6911561' target=_blank style='color:#2F92EE;'>#生殖能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69115, encryptionId=19cf6911561, topicName=生殖能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Nov 24 17:50:36 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764286, encodeId=a8c61e642865c, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Tue Sep 20 20:50:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414473, encodeId=c62614144e36e, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604352, encodeId=c0c31604352d9, content=<a href='/topic/show?id=71b95335396' target=_blank style='color:#2F92EE;'>#感染病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53353, encryptionId=71b95335396, topicName=感染病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=337119178396, createdName=xugc, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079483, encodeId=2f3d10e948340, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3e642424157, createdName=123a16c8m00暂无昵称, createdTime=Mon Dec 13 10:51:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079432, encodeId=83d210e9432e1, content=疫情越来越严重, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195b5478869, createdName=吉星高照4739, createdTime=Mon Dec 13 09:14:35 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-13 123a16c8m00暂无昵称

    受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2061277, encodeId=e1af20612e723, content=<a href='/topic/show?id=19cf6911561' target=_blank style='color:#2F92EE;'>#生殖能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69115, encryptionId=19cf6911561, topicName=生殖能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Nov 24 17:50:36 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764286, encodeId=a8c61e642865c, content=<a href='/topic/show?id=967b66e9727' target=_blank style='color:#2F92EE;'>#激增#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66797, encryptionId=967b66e9727, topicName=激增)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa237702659, createdName=ms1756883563247400, createdTime=Tue Sep 20 20:50:36 CST 2022, time=2022-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414473, encodeId=c62614144e36e, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604352, encodeId=c0c31604352d9, content=<a href='/topic/show?id=71b95335396' target=_blank style='color:#2F92EE;'>#感染病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53353, encryptionId=71b95335396, topicName=感染病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=337119178396, createdName=xugc, createdTime=Tue Dec 14 22:50:36 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079483, encodeId=2f3d10e948340, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3e642424157, createdName=123a16c8m00暂无昵称, createdTime=Mon Dec 13 10:51:35 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079432, encodeId=83d210e9432e1, content=疫情越来越严重, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=195b5478869, createdName=吉星高照4739, createdTime=Mon Dec 13 09:14:35 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-13 吉星高照4739

    疫情越来越严重

    0

相关资讯

五项针对奥密克戎(Omicron)突变株的血清学研究发布,在考虑“要不要换加强针?”

辉瑞/BioNTech公布的BNT162b2针对Omicron的血清学研究结果很让人失望,因为提示:“尽管3剂加强针后1个月时对Omicron有保护力,但2剂接种后3周时预防Omicron

2021年12月11日简报:南非奥密克戎几乎完全取代Delta感染,展示超强竞争力;全球多国奥密克戎感染病例骤增,在几天内成为主要流行毒株;奥密克戎可能不会导致严重疾病,仍需2-3周确定

截至北京时间2021年12月11日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6938万例,新增594,130例,达到269,382,

2021年12月12日简报:奥密克戎让大部分中和抗体失效,但是预计到明年春天,全球疫情全缓和

截至北京时间2021年12月12日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6995万例,新增488,458例,达到269,956,

2021年12月9日简报:全球奥密克戎变种亚型出现,难以被检测;辉瑞疫苗对奥密克戎阻断力下降41倍,美国加强针接种速度破记录

截至北京时间2021年12月9日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6805万例,新增645,380例,达到268,054,6

2021年12月10日简报:多数奥密克戎变异株感染病例症状轻微,中国新冠特效药中和抗体获批上市

截至北京时间2021年12月10日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿6870万例,新增601,434例,达到268,703,

中和抗体能对抗奥密克戎(Omicron)突变株吗?谢晓亮教授给您答案(附下载)

12月8日,国家药监局应急批准腾盛华创医药技术(北京)有限公司新冠病毒中和抗体联合治疗药物安巴韦单抗注射液及罗米司韦单抗注射液注册申请,用于新冠病毒感染的治疗,这是我国第一款治疗新冠的特效药。